Larimar Therapeutics (LRMR) Share-based Compensation: 2013-2020
Historic Share-based Compensation for Larimar Therapeutics (LRMR) over the last 7 years, with Dec 2020 value amounting to $1.0 million.
- Larimar Therapeutics' Share-based Compensation rose 3382.76% to $1.0 million in Q4 2020 from the same period last year, while for Dec 2020 it was $2.2 million, marking a year-over-year decrease of 0.41%. This contributed to the annual value of $8.8 million for FY2024, which is 15.51% up from last year.
- Per Larimar Therapeutics' latest filing, its Share-based Compensation stood at $1.0 million for Q4 2020, which was up 172.97% from $370,000 recorded in Q3 2020.
- In the past 5 years, Larimar Therapeutics' Share-based Compensation ranged from a high of $2.9 million in Q2 2016 and a low of $29,000 during Q4 2019.
- Its 3-year average for Share-based Compensation is $1.2 million, with a median of $881,000 in 2020.
- Per our database at Business Quant, Larimar Therapeutics' Share-based Compensation slumped by 98.76% in 2019 and then soared by 3,382.76% in 2020.
- Larimar Therapeutics' Share-based Compensation (Quarterly) stood at $2.0 million in 2016, then rose by 4.73% to $2.1 million in 2017, then rose by 8.94% to $2.3 million in 2018, then tumbled by 98.73% to $29,000 in 2019, then skyrocketed by 3,382.76% to $1.0 million in 2020.
- Its Share-based Compensation was $1.0 million in Q4 2020, compared to $370,000 in Q3 2020 and $752,000 in Q2 2020.